Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
Michel Dominique FerrariUwe ReuterPeter J GoadsbyGabriel Paiva da Silva LimaSubhayan MondalShihua WenNadia TenenbaumShaloo PandhiMichel Lanteri-MinetTracy StitesPublished in: Journal of neurology, neurosurgery, and psychiatry (2021)
NCT03096834.
Keyphrases